Genetic Discovery Could Help Guide Doctors’ Treatment of Bladder Cancers

Posted: October 16, 2013 at 10:43 pm

A UC San Francisco-led team of scientists has discovered that a gene mutation found in some bladder cancers is indicative of low-risk tumors that are unlikely to recur or progress after surgery.

The finding could help doctors spare many patients from uncomfortable, expensive follow-up tests.

David Solomon, MD, PhD

The study, reported online in the journal Nature Genetics on Oct. 13 offers a glimpse into the potential of precision medicine, which aims to use genetic information to make an accurate analysis of an individuals disease and target it with precise therapy.

The fifth most common malignancy in the U.S., bladder cancers claim about 15,000 lives each year.

A majority of bladder cancers known as papillary tumors can be successfully treated with surgery, but about 20 percent recur and invade the muscle wall of the bladder or spread to nearby organs andlymph nodes. Thus far, physicians have not had an accurate method to determine which papillary tumors are potentially lethal, so most patients undergo frequent endoscopic examinations of their bladder using a technique known as cystoscopy to look for signs of recurrence.

In 2011, while at Georgetown University School of Medicine, David A. Solomon, MD, PhD, his mentor Todd Waldman, MD, PhD, and colleagues published research in Science showing that mutations that deactivate a gene called STAG2 which regulates the separation of duplicate chromosomes during cell division are present in a range of human cancers.

In the top image, STAG2 is expressed in a robust and orderly fashion in normal

Read the original here:
Genetic Discovery Could Help Guide Doctors’ Treatment of Bladder Cancers

Related Posts

Comments are closed.

Archives